Treatment compliance and effectiveness of a cognitive behavioural intervention for low back pain : a complier average causal effect approach to the BeST data set by Knox, Christopher R. et al.
 http://wrap.warwick.ac.uk  
 
 
 
 
 
 
 
 
 
 
Original citation: 
Knox, Christopher R., Lall, Ranjit, Hansen, Zara and Lamb, Sarah E.. (2014) Treatment 
compliance and effectiveness of a cognitive behavioural intervention for low back pain : 
a complier average causal effect approach to the BeST data set. BMC Musculoskeletal 
Disorders, Volume 15 . Article number 17. ISSN 1471-2474 
 
Permanent WRAP url: 
http://wrap.warwick.ac.uk/59109        
       
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions. 
 
This article is made available under the Creative Commons Attribution 2.0 Generic (CC 
BY 2.0) license and may be reused according to the conditions of the license.  For more 
details see: http://creativecommons.org/licenses/by/2.0/ 
 
A note on versions: 
The version presented in WRAP is the published version, or, version of record, and may 
be cited as it appears here. 
 
For more information, please contact the WRAP Team at: publications@warwick.ac.uk  
Knox et al. BMC Musculoskeletal Disorders 2014, 15:17
http://www.biomedcentral.com/1471-2474/15/17RESEARCH ARTICLE Open AccessTreatment compliance and effectiveness of a
cognitive behavioural intervention for low back
pain: a complier average causal effect approach
to the BeST data set
Christopher R Knox1, Ranjit Lall1, Zara Hansen1 and Sarah E Lamb1,2*Abstract
Background: Group cognitive behavioural intervention (CBI) is effective in reducing low-back pain and disability in
comparison to advice in primary care. The aim of this analysis was to investigate the impact of compliance on
estimates of treatment effect and to identify factors associated with compliance.
Methods: In this multicentre trial, 701 adults with troublesome sub-acute or chronic low-back pain were recruited
from 56 general practices. Participants were randomised to advice (control n = 233) or advice plus CBI (n = 468).
Compliance was specified a priori as attending a minimum of three group sessions and the individual assessment.
We estimated the complier average causal effect (CACE) of treatment.
Results: Comparison of the CACE estimate of the mean treatment difference to the intention-to-treat (ITT) estimate
at 12 months showed a greater benefit of CBI amongst participants compliant with treatment on the Roland Morris
Questionnaire (CACE: 1.6 points, 95% CI 0.51 to 2.74; ITT: 1.3 points, 95% CI 0.55 to 2.07), the Modified Von Korff
disability score (CACE: 12.1 points, 95% CI 6.07 to 18.17; ITT: 8.6 points, 95% CI 4.58 to 12.64) and the Modified von
Korff pain score (CACE: 10.4 points, 95% CI 4.64 to 16.10; ITT: 7.0 points, 95% CI 3.26 to 10.74). People who were
non-compliant were younger and had higher pain scores at randomisation.
Conclusions: Treatment compliance is important in the effectiveness of group CBI. Younger people and those with
more pain are at greater risk of non-compliance.
Trial registration: Current Controlled Trials ISRCTN54717854.
Keywords: Compliance, CACE analysis, Low back pain, Cognitive behaviour therapyBackground
A common problem in clinical trials, as well as clinical
practice, is the failure of patients to fully comply with the
allocated treatment. In trials of therapist-led intervention
packages non-compliance occurs when individuals rando-
mised to the intervention do not attend the number of
sessions deemed sufficient for the intervention to deliver a
benefit. In a conventionally used intention-to-treat (ITT)* Correspondence: sarah.lamb@ndorms.ox.ac.uk
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reproduction in any medium, provided the oranalysis all participants are analysed according to their
treatment allocation even if they attend few or none of the
therapy sessions. The intention-to-treat estimate provides
an estimate for the effect of being offered the intervention
when often our interest lies in the effect of receiving the
treatment.
Complier-average causal effect (CACE) modelling is an
analytic approach that provides a robust estimate of the
treatment effect amongst compliant participants [1]. We
specified a priori that compliance was likely to be an im-
portant contributor to the effect of group cognitive
behavioural therapy, and designed a trial that was suffi-
ciently pragmatic to allow estimation of these effects in ad. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sence of published guidance, we defined compliance as
attendance at the assessment session plus three of the six
group sessions as we hypothesised that this would enable
the key components of the cognitive behavioural inter-
vention to be delivered, although not necessarily re-
enforced. In the original intention-to-treat analysis, we
demonstrated that group cognitive therapy was effective
at and beyond 12 months in a range of clinically relevant
outcome measures, with standardised effect sizes mostly
in the moderate range [3,4].
Here our aim was to investigate the nature and impact
of non-compliance on the outcomes of group based cog-
nitive behavioural intervention reported by Lamb et al.
[3]. In non-technical terms, the concept of CACE is
predicated as follows. At the outset of a trial, we assume
that all participants have an unobservable characteristic
(or set of characteristics, known as a latent variable) that
determines whether they would comply or not with the
test intervention. With randomisation, we assume that
these characteristics are equally distributed across each
arm of the trial, and that the proportion of “would be
compliers with the test intervention” is therefore also
equally distributed across the trial arms [5,6]. Only those
randomised to the test arm have the opportunity to
comply with the intervention and we are able to observe
the proportion of compliers in the test arm. Because the
proportion of would be compliers is equally distributed
at the outset, we are able to estimate the proportion in
the control group, from the proportion that are observed
in the treatment group. We are also able to infer the un-
observed mean of the non-compliers in the control
group, from the observed average of the non-compliers
in the treatment group. By representing the treatment
difference observed through intention to treatment ana-
lysis as a product of the proportion of compliers and the
complier averaged difference, and then re-organising the
algebra, it is possible to estimate the complier averaged
difference (CACE). Assumptions about missing data are
important, and further refinement is added by inclusion
of baseline co-variates through more sophisticated statis-
tical techniques. An important assumption is that the
offer of the intervention does not influence the outcome
[7]. Non-compliers should, on average, have the same
mean score in the intervention group as the control
group [8,9].
Methods
Participants and procedures
The Back Skills Training (BeST) Trial was a multicentre
randomised controlled trial and the design, intervention,
and main analyses have been reported in detail elsewhere
[2,3,10,11]. In short, 701 participants over 18 years of age
were recruited from primary care with at least moderatelytroublesome nonspecific low back pain (LBP) present for
greater than 6 weeks. Participants were randomised, in a
ratio of 1:2 respectively, to advice alone (control) or advice
plus cognitive behavioural intervention.
All participants received a 15-minute session of active
management advice, which included advice on remaining
active, avoidance of bed rest, appropriate use of pain
medication and symptom management, supplemented by
a copy of The Back Book [12].
In addition, participants in the intervention group
attended the Back Skills Training (BeST) programme, con-
sisting of an individual assessment (up to 1.5 hours dur-
ation) and six sessions of group therapy (1.5 hours
duration each) using a cognitive–behavioural approach.
We aimed for a group size of about 8 participants facili-
tated by one therapist. We trained 19 therapists (14 Phys-
iotherapists, 2 Occupational Therapists, 2 psychologists
and 1 nurse) to deliver the programme over a 2-day train-
ing course. The intervention has been described in detail
elsewhere [10]. Relevant to this paper is the content and
sequence of material in each of the sessions. The assess-
ment session aimed to gather information about the par-
ticipant’s history of LBP and identify any unhelpful beliefs
that the participant might have about their LBP. The as-
sessment was also an opportunity to set three collabora-
tive treatment goals, one of which we pre-specified as an
exercise/physical activity goal because of the recognised
importance of physical activity for managing low back
pain. In addition the concepts of baseline setting and
pacing were introduced during the assessment session.
Thereafter the group sessions were structured around the
themes shown in Table 1. Therapists were provided with a
detailed manual describing all of the procedures for each
session, and supporting materials. Each participant was
provided with a summary at the end of each session, along
with “homework” to practice before the next session, such
as relaxation techniques. Those people not attending a
session were mailed out the session summaries and home-
work. We recorded attendance of participants along with
reasons for non-attendance, where provided.
Outcome measurements
Data were collected by postal questionnaire at 3, 6 and
12 months after randomisation. The primary outcomes
were the Roland Morris Disability Questionnaire
(RMDQ; scale 0–24, where lower scores indicate less se-
vere disability) [13] and modified Von Korff (MVK)
scales of pain and disability (scale 0–100%, where lower
scores indicate less pain and disability) [14]. Generic
health-related quality of life was collected using the EQ-
5D (scale −0.594 to 1, where lower scores indicate
poorer quality of life) [15]. Telephone follow-up was
attempted for the modified Von Korff scale in cases of
non-response to the postal questionnaire.
Table 1 Details of the contents of the cognitive behavioural intervention group sessions
Session number 1 2 3 4 5 6
Assessment
History taking including current problems and eliciting beliefs on LBP and activity
Collaborative goal setting with plan to start activity goal
Exercises chosen collaboratively from options with level negotiated
Exercises practised and progression discussed
Understanding pain ✓
Group activity to demonstrate hurt does not equal harm
Current thinking on causes of long-term pain explained
Discussion on groups experience of alternative treatments for LBP with reference to research evidence and need to self manage
Benefits of exercise ✓
Discussion of physical impact of inactivity or altered activity and how changes impact on pain (disuse syndrome)
Discussion on effects of activity/exercise
Introduction to LBP model
Pain fluctuations ✓
Overactivity/underactivity cycle explained
Use of pacing
Group problem solving for a specific task that tends to be ‘overdone’ e.g. gardening
Working out starting point for exercises or activities ✓
How to use baseline setting
How to set goals ✓
SMART system used to break down an example goal
Feedback from group on how progressing with goals from assessment
Group problem-solving problems with goals
Unhelpful thoughts and feelings ✓
Styles of unhelpful thinking discussed, including catastrophising
Link with unhelpful behaviours
Identifying unhelpful thoughts
Group problem-solving for challenging unhelpful thoughts
Restarting activities or hobbies ✓
Discussion on activities commonly avoided in LBP
Fear avoidance cycle
Group problem-solving out of cycle
Development of specific goals relating to restarting activities
When pain worries us ✓
Effect of attention to pain explored through group activity
Hypervigilance cycle used to link unhelpful thoughts and behaviours
Group problem-solving out of cycle
Discussion on the use of medication/distraction/alternating activities
Coping with flare-ups ✓
Discussion on causes of flare-ups
Plan of what to do in and out of flare-ups
Revision of topics over previous sessions and questions
LBP, lower back pain.
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The West Midlands Multi-centre Research Ethics Com-
mittee approved the trial protocol and longer-term
follow-up (MREC/03/7/04). All participants gave written
informed consent.
Definition of compliance
Compliance was defined a priori as attendance at the
initial assessment and at least three subsequent sessions.
The cognitive behavioural intervention was only avail-
able to participants randomly allocated to receive it and
so compliance status is only observable in the interven-
tion group. Compliance was observed at the intervention
stage of the study. Loss to follow up is still used to refer
to patients for whom it was not possible to collect out-
come data at the follow-up time points.
Statistical analysis
We examined the baseline characteristics of participants
randomised to the CBI arm, by compliance status. In
addition, we report the baseline characteristics of partici-
pants randomised to the control arm.
The effect of treatment was estimated as the mean
change scores from baseline as this was the only method
that remedied substantial skew in the data, and was con-
sistent with the original analysis [2,3]. We produced
summary estimates of the treatment effect for compliers
and non-compliers in the intervention arm using linear
regression analysis adjusted for baseline covariates as
specified in the original analysis. This included adjust-
ment for the baseline value of the change score.
We produced CACE estimates of the difference be-
tween the mean score for the compliers in the interven-
tion group compared to the would-be compliers in the
control group [16]. To obtain a CACE estimate we used
a latent class model approach using the gllamm com-
mand in STATA [9,17,18]. This CACE model estimates
the compliers in the control group and compares these
to the observed compliers in the intervention group to
estimate a treatment effect amongst compliers. The
amount of unobserved compliers in the control group
can be estimated using the proportion of compliers in
the intervention group based on the assumption that the
proportion of compliers is balanced across the treatment
arms [5,6]. All participants were analysed according to
their treatment allocation.
A CACE model including baseline covariates associ-
ated with the two responses, compliance for the inter-
vention arm and outcome for the whole sample, was
fitted and compared to a null model using the likelihood
ratio test. The compliance part of the model was ad-
justed for age and baseline modified Von Korff score as
these were found to be associated with compliance. The
outcome part of the model is adjusted for the baselinecovariates of age, gender, severity of back pain, centre
and baseline values of the outcome score as specified in
the original BeST analysis [3].
The analysis includes all eligible randomised partici-
pants who provided follow-up data. Our CACE analysis
assumes that whether or not a participant provides
follow-up data is determined by their compliance status
and so missing data is ignorable [8,19]. Sensitivity to
missing data was investigated using a multiple imput-
ation analysis. Estimates from the CACE model were
compared to ITT estimates from an adjusted linear re-
gression with participants analysed according to alloca-
tion assignment regardless of compliance. We provide a
qualitative comparison of the CACE and ITT models
using the standardised effect size (calculated as the un-
adjusted mean difference between the groups divided by
the pooled standard deviation at baseline). The CACE
analysis was repeated with compliance re-defined as at-
tendance at the individual assessment, attendance at the
individual assessment and one or more group therapy
sessions and two or more group therapy sessions. A
range of outcomes were analysed at 3, 6 and 12 months
and all analyses were carried out using STATA version
11 [18].
Results
Participants
Of the 701 randomised participants 598 (85%) provided
12-month follow up data (advice alone n = 199/233
(85%); advice plus cognitive behavioural intervention,
n = 399/468 (85%)). For the outcome measures used in
the CACE analyses the number of contributing partici-
pants ranged from 498 with complete Roland Morris
questionnaire scores at 12 months to 587 with complete
modified Von Korff pain scores and EQ-5D scores at 12
months, with no difference in the levels of missing data
between treatment groups. Due to missing data in the
outcome and predictors the number of participants used
in the analyses differs for each month and outcome
score. The number of participants in the ITT analysis is
the same is in the CACE analysis for each month and
outcome score. There was one participant randomised
to the advice group who received the cognitive behav-
ioural intervention. They were analysed as intention to
treat.
Levels of attendance at the cognitive behavioural assess-
ment and group sessions are shown in Figure 1. Of the
468 participants assigned to cognitive behavioural inter-
vention, 174 (37%) did not achieve the compliance thresh-
old. For the non-compliant group, 50/174 (29%) people
did not attend the assessment or sessions, and 59/174
(34%) attended the assessment only. The remainder of
people who were non-compliant (65/174) attended the as-
sessment and an average of 1.5 (SD 0.50) sessions. The
Figure 1 Attendance at cognitive behavioural intervention sessions by compliers and non-compliers. Number of compliers (n = 294) and
non-compliers (n = 174) in the CBI group (n = 468) attending each cognitive behavioural intervention session with a maximum of six sessions plus
the initial individual assessment.
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group was 5.1 (SD 0.91).
We obtained reasons for non-attendance from 78
(45%) of the non-compliers. The primary reasons given
for not attending were feeling unwell (18/78 (10%)),
changes to work (15/78 (9%)) and family issues (14/78
(8%)). The attainment of the compliance threshold was
broadly similar across the different centres (22/38 (58%)
to 84/127 (66%)), as were patterns of missing data. The
number of patients reaching the compliance threshold
varied across the 19 therapists (3/8 (38%) to 4/5 (80%)).
However, there was less deviation in the complier num-
bers where there were more than 10 patients per therap-
ist (8/15 (53%) to 13/18 (72%)).
Loss to follow up was significantly associated with
compliance. At 12 months 113 out of 174 (65%) non-
compliers provided a modified Von Korff pain score,
compared with 279 out of 294 (95%) compliers (chi
squared p-value < 0.001). On the Roland Morris ques-
tionnaire 72 out of 174 (41%) non-compliers provided
complete data, compared to 267 out of 294 (91%) com-
pliers (chi squared p-value < 0.001).
Complier characteristics
Table 2 shows the baseline characteristics of the com-
pliers and non-compliers in the intervention group. No-
ticeably, in comparison to non-compliers, compliers
were older (mean difference 4.5 years, 95% CI 1.8-7.2),
had a longer duration of back pain (mean difference 2.8
years, 95% CI 0.2-5.3), had less frequent back pain (odds
ratio 0.5, 95% CI 0.3-0.8) and had lower baseline modi-
fied Von Korff pain scores (mean difference 4.6 points,95% CI 0.9-8.2). In multi-variate analysis, two baseline
factors emerged as being associated with compliance.
These were age (odds ratio 1.02, 95% CI 1.01-1.04), and
a worse modified Von Korff pain score (odds ratio 0.99,
95% CI 0.98-1.00).
Adjusted estimates of the mean scores on the Roland
Morris questionnaire, modified Von Korff score and EQ-
5D are reported by intervention arm and by compliance
status in Table 3. The effect of compliance was most evi-
dent on the pain and disability outcomes at the time
points closest to the intervention delivery, where com-
pliers experienced at least a doubling of response in
comparison to non-compliers. By the 12 month follow
up, non-compliers had recovered to a similar level as the
compliers, the only exceptions being the Modified Von
Korff Disability score at 12 months, where compliers
continued to report greater benefits from the cognitive
behavioural intervention. Compliers experienced greater
gains in EQ-5D scores at 3 months and these remained
stable thereafter, whereas non-compliers reported a
gradual improvement in EQ-5D, with no statistically sig-
nificant difference by compliance status at either 6 or 12
months.
Estimates of the CACE model
The ITT and CACE estimates of the treatment effect are
reported in Table 4. Co-variate adjustment for the CACE
model provided a statistically significant better fit for all
models (Likelihood Test p < 0.001 for all models), and
hence only these models are reported. In all CACE
models, with the exception of the Roland Morris ques-
tionnaire, the estimate of the mean treatment difference
Table 2 Baseline characteristics of randomised participants by compliance status; complier, non-complier or control
Advice plus cognitive behavioural intervention (n = 468)
Control Complier Non-complier Mean difference* p value†
(n = 233) (n = 294) (n = 174) (95% CI)
Age (years) 54.1 (14.9) 55.0 (14.3) 50.5 (14.8) 4.5 (1.8, 7.2) 0.001
Sex - 0.694
Female 142 (60.9%) 173 (58.8%) 105 (60.3%)
Male 90 (38.6%) 121 (41.2%) 68 (39.1%)
Missing 1 (0.4%) 0 1 (0.6%)
Ethnic origin - 0.258
White 206 (88.4%) 268 (91.2%) 144 (82.8%)
Mixed 3 (1.3%) 2 (0.7%) 2 (1.1%)
Asian 8 (3.4%) 9 (3.1%) 12 (6.9%)
Black 4 (1.7%) 4 (1.4%) 3 (1.7%)
Chinese 1 (0.4%) 1 (0.3%) 0
Missing 11 (4.7%) 10 (3.4%) 13 (7.5%)
Severity of back pain - 0.802
Moderately troublesome 130 (55.8%) 157 (53.4%) 95 (54.6%)
Very or extremely troublesome 103 (44.2%) 137 (46.6%) 79 (45.4%)
Age left full-time education (years) - 0.584
≤16 121 (51.9%) 168 (57.1%) 98 (56.3%)
17-19 61 (26.2%) 65 (22.1%) 39 (22.4%)
≥20 49 (17.2%) 48 (16.3%) 25 (14.4%)
Still in full-time education 2 (0.9%) 0 1 (0.6%)
Missing 9 (3.9%) 13 (4.4%) 11 (6.3%)
In employment† - 0.612
Yes 110 (47.2%) 147 (50.0%) 91 (52.3%)
No 122 (52.4%) 146 (49.7%) 82 (47.1%)
Retired 77 (63.1%) 94 (64.4%) 36 (43.9%)
At home not looking for work 4 (3.3%) 12 (8.2%) 13 (15.9%)
Unable to work because of back pain 11 (9.0%) 12 (8.2%) 10 (12.2%)
Unable to work because of other illness 9 (7.4%) 10 (6.8%) 6 (7.3%)
Unemployed and looking for work 8 (6.6%) 1 (0.7%) 3 (3.7%)
In full-time education 2 (1.6%) 0 0
Other 3 (2.5%) 1 (0.7%) 5 (6.1%)
Reason not given 8 (6.6%) 16 (11.0%) 9 (11.0%)
Duration of back pain (years since first onset) 13.2 (12.7) 14.1 (14.2) 11.4 (11.2) 2.8 (0.2, 5.3) 0.034
Frequency of back pain (past 6 weeks) - 0.009
Everyday 162 (69.5%) 189 (64.3%) 126 (72.4%)
Less often than everyday 47 (20.2%) 82 (27.9%) 29 (16.7%)
Missing 24 (10.3%) 23 (7.8%) 19 (10.9%)
Roland Morris questionnaire 8.5 (4.7) 8.6 (4.9) 9.1 (5.2) −0.4 (−1.4, 0.5) 0.357
Modified Von Korff disability 46.2 (23.8) 47.0 (23.6) 51.0 (24.1) −4.0 (−8.6, 0.5) 0.083
Modified Von Korff pain 59.4 (19.5) 57.6 (19.3) 62.2 (18.9) −4.6 (−8.2, -1.0) 0.014
EQ-5D 0.6 (0.3) 0.6 (0.3) 0.5 (0.3) 0.1 (−0.01, 0.1) 0.082
Data are mean (SD) or n (%). Participants in the control group were assigned to receive advice only.
*Mean difference between compliers and non-compliers in cognitive behavioural intervention arm.
†Reported p values are from t test where mean differences are reported and chi-squared tests elsewhere.
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Table 3 ITT estimates of clinical effectiveness at 3, 6 and 12 months
All Advice plus cognitive behavioural intervention
Control Advice plus cognitive behaviouralintervention Non-complier Complier
Mean compliance difference
(95% CI)*
p value
Mean change from baseline
(95% CI)*
Mean change from baseline
(95% CI)*
Roland Morris Questionnaire (points)†
3 months 0.9 (0.32, 1.53) 2.0 (1.55, 2.46) 0.9 (−0.06, 1.83) 2.3 (1.82, 2.85) 1.5 (0.44, 2.47) 0.005
6 months 1.0 (0.38, 1.64) 2.5 (1.98, 2.92) 1.6 (0.68, 2.58) 2.7 (2.18, 3.21) 1.0 (−0.00, 2.07) 0.05
12 months 1.0 (0.36, 1.70) 2.3 (1.86, 2.82) 2.1 (1.12, 3.07) 2.5 (1.99, 3.09) 0.4 (−0.62, 1.52) 0.41
Modified Von Korff disability (%)†
3 months 8.8 (5.42, 12.14) 13.4 (10.81, 16.03) 6.5 (1.27, 11.65) 14.6 (11.56, 17.71) 8.2 (2.51, 13.82) 0.005
6 months 5.7 (2.17, 9.19) 14.0 (11.43, 16.60) 9.0 (4.30, 13.67) 15.2 (12.07, 18.42) 6.3 (0.99, 11.53) 0.02
12 months 5.3 (1.82, 8.78) 13.9 (11.32, 16.50) 10.0 (5.48, 14.60) 16.0 (12.88, 19.12) 6.0 (0.78, 11.14) 0.024
Modified Von Korff pain (%)†
3 months 5.4 (2.41, 8.30) 12.3 (10.02, 14.51) 7.4 (2.85, 11.87) 13.6 (10.94, 16.22) 6.2 (1.31, 11.12) 0.013
6 months 5.6 (2.27, 8.85) 13.8 (11.38, 16.18) 8.8 (4.44, 13.24) 15.5 (12.51, 18.41) 6.6 (1.67, 11.58) 0.009
12 months 6.4 (3.12, 9.62) 13.4 (10.98, 15.76) 11.6 (7.28, 15.85) 14.4 (11.52, 17.21) 2.8 (−2.05, 7.65) 0.257
EQ-5D
3 months 0.5 (0.51, 0.58) 0.6 (0.59, 0.65) 0.6 (0.50, 0.61) 0.6 (0.59, 0.66) 0.1 (0.01, 0.13) 0.014
6 months 0.6 (0.54, 0.62) 0.6 (0.59, 0.65) 0.6 (0.55, 0.64) 0.6 (0.60, 0.66) 0.03 (−0.03, 0.09) 0.293
12 months 0.6 (0.54, 0.61) 0.6 (0.60, 0.66) 0.6 (0.56, 0.66) 0.6 (0.59, 0.66) 0.01 (−0.04, 0.07) 0.616
Estimates of disability, pain and health related quality of life at 3, 6 and 12 months for all participants (ITT) and for compliers and non-compliers in the advice plus
cognitive behavioural intervention arm with the difference between compliers and non-compliers.
Participants in the control group were assigned to receive advice only.
*Based on a linear regression model adjusted for age, sex, severity of back pain, centre and baseline value.
†The number of participants used in the regression analyses differs for each month on each score; due to missing data in the outcome and predictors.
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comparisons, the lower bound of the 95% confidence
interval was also greater.
The CACE estimate of the treatment difference between
advice alone and advice plus cognitive behavioural therapy
on the Roland Morris questionnaire score is 1.6 points
(95% CI 0.51–2.74) at 12 months. The estimated treat-
ment difference for compliers is 12.1 points (6.07-18.17)
on the Von Korff disability score and 10.4 points (4.64-
16.10) on the Von Korff pain score at 12 months. The esti-
mated treatment difference at 12 months for compliers on
the EQ-5D is 0.07 (0.01-0.14) points. At 12 months the
standardised effect size is increased for all measures using
the CACE analysis. Comparing the ITT estimate to the
CACE estimate in Table 4, the estimate of the standardised
effect size is increased from 0.31 to 0.43 on the Roland
Morris questionnaire, from 0.42 to 0.60 on the Von Korff
disability score and from 0.37 to 0.60 on the Von Korffpain score. There is a threefold increase in the estimate of
the standardised effect size on the EQ-5D, from an ITT
estimate of 0.13 to a CACE estimate of 0.36.
Estimates from CACE analyses redefining compliance
as attendance at the individual assessment only, attend-
ance at the individual assessment and one or more
group therapy sessions and two or more group therapy
sessions are reported in Table 5. Based on definitions of
compliance with a minimum requirement as attendance
at the individual assessment the estimate of the mean
treatment difference is greater than from the ITT ana-
lysis for all outcomes at 6 and 12 months.
CACE model estimates and ITT estimates based on
imputed datasets show a small reduction in the magni-
tude of the treatment difference at 3, 6 and 12 months
with the exception of the Roland Morris questionnaire
at 3 months. The CACE estimates remain greater than
the ITT estimates and conclusion of significance of the
Table 4 ITT and CACE model estimates of treatment difference at 3, 6 and 12 months
ITT covariate model Standardised
effect at 12
months†
CACE covariate model Standardised
effect at 12
months‡
Mean treatment difference (95% CI)* p value Mean treatment difference (95% CI)† p value
Roland Morris Questionnaire (points)
3 months 1.1 (0.39, 1.77) 0.002 .. 1.1 (0.04, 2.22) 0.042 ..
6 months 1.4 (0.72, 2.16) <0.001 .. 1.9 (0.87, 2.98) <0.001 ..
12 months 1.3 (0.55, 2.07) 0.001 0.31 1.6 (0.51, 2.74) 0.004 0.43
Modified Von Korff disability (%)
3 months 4.6 (0.75, 8.52) 0.029 .. 5.4 (−0.38, 11.15) 0.067 ..
6 months 8.3 (4.32, 12.35) <0.001 .. 11.1 (5.30, 16.83) <0.001 ..
12 months 8.6 (4.58, 12.64) <0.001 0.42 12.1 (6.07, 18.17) <0.001 0.60
Modified Von Korff pain (%)
3 months 6.9 (3.53, 10.29) <0.001 .. 8.8 (3.84, 13.82) 0.001 ..
6 months 8.2 (4.48, 11.97) <0.001 .. 11.2 (5.89, 16.61) <0.001 ..
12 months 7.00 (3.26, 10.74) <0.001 0.37 10.4 (4.64, 16.10) <0.001 0.60
EQ-5D
3 months 0.08 (0.033, 0.117) <0.001 .. 0.09 (0.020, 0.161) 0.012 ..
6 months 0.04 (−0.007, 0.080) 0.098 .. 0.06 (−0.011, 0.121) 0.102 ..
12 months 0.05 (0.010, 0.097) 0.015 0.13 0.07 (0.008, 0.141) 0.029 0.36
*Based on a linear regression model adjusted for age, sex, severity of back pain, centre and baseline value.
†Based on a latent class model with outcome adjusted for age, sex, severity of back pain, centre and baseline value and compliance adjusted for age and baseline
modified Von Korff pain score.
‡Standardised effect size is the unadjusted mean difference (standardised mean difference) between the groups divided by the pooled SD at baseline.
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on the imputed data.
Discussion
Few, if any, trials of low back pain interventions have
considered the treatment effect amongst compliers using
robust analyses. Both the complier average causal effect
and linear regression analyses support the concept that
compliance has an important role determining the size of
treatment effect. People who achieved the compliance
threshold achieved a larger benefit in clinical and health
related quality of life outcomes in the year of follow up in
comparison to advice only, than those who are less
compliant.
The estimates from the CACE analysis provide the most
robust indication of the treatment effect amongst com-
pliers, although there are some limitations in the analysis
we present. First is that there is no accepted method of de-
fining compliance to cognitive behavioural interventions.
We based our analysis on the compliance definition set
out in the protocol and have examined different thresh-
olds in further analyses due to potential limitations of this
definition in the analysis model. Our definition of attend-
ance at the initial assessment and three or more sessions
was based on a collective judgement of the intervention
designers that this would provide the essential componentsof the programme. This is broadly in keeping with other
reports in the literature [20]. In those defined as non-
compliers, some may have received some elements of the
cognitive behavioural intervention, and this could possibly
lead to an underestimate of the treatment effect amongst
compliers [21]. All participants of the trial received a
brief, best practice active management advice session
from a nurse or physiotherapist. In the intervention arm,
71% of those deemed non-compliant had attended some
part of the BeST intervention, most commonly the as-
sessment +/− the first or second group session, and had
received the session summary materials for all sessions.
Despite this we still observed a substantial and statistically
significant difference in the treatment effect estimate.
We quantified compliance in terms of treatment at-
tendance. CACE analysis assumes that compliance is a
pre-randomisation characteristic and hence equally dis-
tributed across the treatment arms. Our data supports
the hypothesis that the characteristic of being a complier
is associated with a larger treatment benefit than being a
non-complier. Whether compliance is potentially modi-
fiable, and whether modifying the attendance behaviour
of patients results in better outcomes is less certain.
There are several potential mechanisms by which
compliance is associated with a larger treatment effect.
First is reverse causality, i.e. that compliance is driven by
Table 5 CACE model estimates of treatment difference with re-defined compliance
Assessment only 1 or more group sessions 2 or more group sessions
Mean
treatment
difference
(95% CI)*
p value Standardisedeffect at
12 months‡
Mean
treatment
difference
(95% CI)*
p value Standardisedeffect at
12 months‡
Mean
treatment
difference
(95% CI)*
p value Standardisedeffect at 12
months‡
Roland Morris Questionnaire (points)†
3 months 1.1 (0.30, 1.86) 0.007 .. 0.8 (−0.10, 1.72) 0.079 .. 1.1 (0.07, 2.09) 0.035 ..
6 months 1.4 (0.59, 2.18) 0.001 .. 1.7 (0.80, 2.60) <0.001 .. 1.8 (0.78, 2.74) <0.001 ..
12 months 1.4 (0.61, 2.25) 0.001 0.34 1.5 (0.55, 2.43) 0.002 0.38 1.5 (0.48, 2.56) 0.004 0.40
Modified Von Korff disability (%)†
3 months 4.9 (0.61, 9.14) 0.025 .. 4.6 (−0.27, 9.43) 0.064 .. 5.1 (−0.24, 10.38) 0.061 ..
6 months 8.7 (4.34, 13.07) <0.001 .. 9.6 (4.71, 14.53) <0.001 .. 10.3 (4.97, 15.65) <0.001 ..
12 months 9.4 (4.93, 13.78) <0.001 0.46 10.3 (5.19, 15.35) <0.001 0.52 11.1 (5.57, 16.71) <0.001 0.56
Modified Von Korff pain (%)†
3 months 7.2 (3.53, 10.93) <0.001 .. 7.5 (3.37, 11.73) <0.001 .. 8.2 (3.57, 12.78) <0.001 ..
6 months 8.7 (4.59, 12.76) <0.001 .. 9.7 (5.10, 14.29) <0.001 .. 10.4 (5.43, 15.40) <0.001 ..
12 months 7.9 (3.69, 12.03) <0.001 0.43 8.8 (3.99, 13.58) <0.001 0.50 9.4 (4.08, 14.66) 0.001 0.53
EQ-5D†
3 months 0.1 (0.01, 0.11) 0.015 .. 0.1 (0.02, 0.14) 0.014 .. 0.1 (0.01, 0.14) 0.024 ..
6 months 0.04 (−0.01, 0.09) 0.12 .. 0.04 (−0.01, 1.00) 0.128 .. 0.1 (−0.01, 0.11) 0.102 ..
12 months 0.1 (0.04, 0.13) <0.001 0.40 0.1 (0.01, 0.12) 0.022 0.32 0.1 (0.01, 0.13) 0.023 0.36
CACE model estimates at 3, 6 and 12 months with compliance re-defined as attendance at the individual assessment only, attendance at the individual
assessment and one or more group therapy sessions and two or more group therapy sessions.
*Based on a latent class model with outcome adjusted for age, sex, severity of back pain, centre and baseline value and compliance adjusted for age and baseline
modified Von Korff pain score with the exception of modified Von Korff pain score at 6 months where compliance is only adjusted for age.
†The number of participants used in the regression analyses differs for each month on each score; due to missing data in the outcome and predictors.
‡Standardised effect size is the unadjusted mean difference (standardised mean difference) between the groups divided by the pooled SD at baseline.
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pliance being important to response, the early response
engenders compliance. High pain at study entry (i.e. a
pre-randomisation variable) was associated with non-
compliance. We cannot rule in or out this hypothesis as
we did not take measures of response on a weekly basis.
Future studies could address this issue, and this would
be important in understanding what drives compliance
in the context of low back pain. The second potential
mechanism is that greater attendance results in re-
enforcement of the key components of the intervention.
In designing the intervention some of the concepts were
repeated across sessions, and the therapists were encour-
aged to revisit and draw on the experiences and skills
mastered in prior sessions. Participants undertook regu-
lar review of their treatment goals, and progression to-
ward them. Finally, it is possible that the later sessions
contain elements that are substantially important to the
effect, or that the increasing social contact across re-
peated visits has a therapeutic value.
We are not able to conclude from our results whether
a shorter programme (3 or less sessions) would be as
good as six sessions, as we did not test this explicitly.An important assumption of the CACE analysis, the
exclusion restriction, is that for non-compliers in the
intervention arm there is no additional benefit gained
from the offer of treatment compared to participants
randomised to the advice group [7,9]. In this study par-
ticipants that are randomised to the intervention are
treated as non-compliers even if they might have
attended one or two sessions as well as the individual as-
sessment. We would expect that at least some of these
participants would have received a partial benefit and so
this could violate the exclusion restriction and introduce
bias. We used a CACE model adjusted for covariates as-
sociated with outcome score and compliance which pro-
tects against bias if, as described above, there is violation
of the exclusion restriction assumption [21]. It has also
been shown that bias introduced by violation of the
exclusion criteria is increased in the CACE estimate if
the compliance rate is very low [21]. This was not the
case; compliance within the group cognitive behavioural
therapy was 63%.
Further CACE analyses show that when compliance is
defined as attendance at a minimum of the individual as-
sessment the treatment effect is still estimated to be
Knox et al. BMC Musculoskeletal Disorders 2014, 15:17 Page 10 of 11
http://www.biomedcentral.com/1471-2474/15/17greater than the ITT estimate at 12 months. This is not
unexpected as, in a parallel qualitative study, a number
of the participants of the intervention mentioned how
valuable they found the assessment session independ-
ently of the group sessions [2]. The treatment effect esti-
mates based on attendance at the individual assessment
can be defined as the treatment effect of partial and
complete compliers; it is the treatment effect excluding
complete non-compliers. This provides an unbiased esti-
mate of treatment effect and again demonstrates that
the treatment effect estimated from an ITT analysis is an
underestimate of the actual effect of treatment.
We have compared the estimates from the CACE
model to ITT estimates so that it is comparable to our
original reporting. An as-treated analysis is not reported
as in the presence of non-compliance this method is
considered to be misleading and so does not provide
robust estimates [22].
Missing follow up data was shown to be related to com-
pliance and so identification of non-compliers could be
useful in managing the collection of follow up data. It also
follows that if compliance rates can be increased through
encouraging attendance at all sessions then this should
lead to an increase in the completeness of follow up data.
Under the missing at random assumption used in this
CACE analysis the outcome response behaviour is permit-
ted to differ between complier groups in the intervention
arm [23]. There is also evidence from prior methodo-
logical work that CACE estimates produced from latent
class modelling are insensitive to the missing data assump-
tion used, missing at random or latent ignorability [24].
We undertook additional sensitivity analyses using multi-
ply imputed datasets, and these suggest that the CACE re-
sults are insensitive to the missing data.
The latent class modelling approach used here to de-
rive CACE estimates does not account for clustering ef-
fects such as therapist effects. It is possible to undertake
analyses including clustering in a model accounting for
non-compliance as demonstrated by B Jo, T Asparouhov
and BO Muthén [25]. However, our original ITT ana-
lyses demonstrated therapist and group effects were
negligible.
This analysis shows that the effectiveness of group
cognitive behavioural intervention is increased in com-
pliers. Whilst we cannot be sure that compliance is a
modifiable trait, research from other areas suggest that it
is, and issues such as family and work commitments in
scheduling of sessions, or even in the mode of delivery
(for example requiring attendance at a face to face meet-
ing), may render better compliance [26]. We did not use
specific behavioural techniques to encourage attendance
at the sessions (i.e. attendance at sessions was not identi-
fied as a goal), and this approach may add to improved
compliance.There are examples in the literature of analysis of trials
subject to non-compliance but these are mainly limited
to social interventions and trials of psychological treat-
ments [8,22,27]. This current paper is distinctive in pro-
viding a CACE analysis of a trial of sub-acute or chronic
low-back pain. CACE estimates are potentially more
clinically relevant than effect estimates derived from ITT
analyses and give a better indication of the effect of re-
ceiving treatment.
Conclusion
Exploration of compliance data and use of a CACE ana-
lysis can aid the interpretation of the primary results of
randomised trials. CACE analysis provides a means of
estimating the effect of the receipt of treatment in a ran-
domised trial in which not all patients were compliant.
Supplementing estimates from an ITT analysis with
CACE estimates helps to provide a more complete pic-
ture of the pragmatic effects of an intervention that can
support clinical decision making.
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